AMLXAmylyx Pharmaceuticals, Inc.
Pharmaceutical Preparations
- Revenue
- $0
- 100% YoY
- Operating margin
- —
- EBITDA
- −$153M
- 51% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear—Over 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $285K | $22M | $381M | $87M | $0 | 100% |
| Operating income | −$83M | −$201M | $39M | −$315M | −$153M | 51% |
| Net income | −$88M | −$198M | $49M | −$302M | −$145M | 52% |
| Operating cash flow | −$75M | −$180M | $12M | −$168M | −$123M | 26% |
| Capex | $353K | $3M | $1M | $157K | $138K | 12% |
| Stock-based comp | $3M | $22M | $37M | $33M | $28M | 16% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $4M · 11
- Net
- −$4M
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 67 | — |
| FY2024 | — | — | 21 | — |
| FY2023 | — | — | 81 | — |